SEMA3F Antibody

What is SEMA3F and why is it important for researchers to study?

SEMA3F (semaphorin 3F) is a secreted protein belonging to the semaphorin family with a molecular mass of approximately 88.4 kDa and 785 amino acid residues in humans. It plays crucial roles in cell motility and cell adhesion processes across various neural and non-neural tissues . SEMA3F has garnered significant research interest due to its involvement in inflammation regulation and potential tumor suppressor functions. The gene encoding SEMA3F is located on chromosome 3p21.3, a region frequently showing loss of heterozygosity in lung and breast cancers, suggesting its role in tumor suppression . Understanding SEMA3F's diverse biological functions provides insights into disease mechanisms and potential therapeutic targets.

How do I select the most appropriate anti-SEMA3F antibody for my research?

Selection of the appropriate anti-SEMA3F antibody depends on several experimental factors:

• Target species: Confirm the antibody's reactivity matches your species of interest (human, mouse, rat, etc.). SEMA3F is conserved across species including mouse, rat, bovine, frog, and chimpanzee .

• Application requirements: Different experimental techniques require antibodies validated for specific applications. Anti-SEMA3F antibodies are commonly used in Western blot, but many are also validated for IHC, ICC, ELISA, and IF .

• Epitope specificity: Consider whether you need antibodies targeting specific domains (N-terminal, C-terminal) or isoforms of SEMA3F, as up to two different isoforms have been reported .

• Clonality: Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes and may provide stronger signals.

• Validation data: Review literature citations where specific anti-SEMA3F antibodies have been successfully employed in similar experimental contexts .

For investigations involving receptor interactions, select antibodies that don't interfere with the binding regions between SEMA3F and its neuropilin receptors.

What are the known receptors for SEMA3F and how does this affect antibody selection?

SEMA3F primarily interacts with neuropilin-1 (NRP1) and neuropilin-2 (NRP2) receptors, with studies suggesting higher affinity for NRP2. This receptor binding mediates its biological effects, including repulsive activities on cell migration and inhibition of cell spreading .

When selecting antibodies for studying SEMA3F-receptor interactions:

• Choose antibodies that don't interfere with the receptor-binding domains if you're studying function.

• For receptor-blocking studies, specifically select antibodies that target the SEMA3F-NRP binding interface.

• Consider using anti-NRP2 antibodies alongside anti-SEMA3F antibodies when investigating signaling mechanisms, as NRP2 blockade has been shown to inhibit SEMA3F's repulsive effects on certain cancer cell lines (e.g., C100 cells) .

Research has demonstrated that SEMA3F competes with vascular endothelial growth factor (VEGF) for binding to neuropilin receptors, suggesting an important regulatory mechanism in both developmental and pathological contexts .

What are the optimal methodologies for detecting SEMA3F using antibodies in different tissue types?

Detecting SEMA3F across different tissue types requires optimization of protocols based on tissue-specific characteristics and expression levels:

For neural tissues (high endogenous SEMA3F expression):

• Immunohistochemistry (IHC): Use antigen retrieval with citrate buffer (pH 6.0), followed by overnight incubation with anti-SEMA3F antibody (1:100-1:200 dilution).

• Reduce background staining with extended blocking (5% normal serum, 2 hours) before antibody application.

For lung and inflammatory tissues:

• Both frozen and formalin-fixed paraffin-embedded (FFPE) sections have been successfully used with anti-SEMA3F antibodies .

• For neutrophil-rich inflammatory tissues, dual staining with neutrophil markers can help distinguish SEMA3F-producing cells.

• In COPD lung sections, successful staining has been reported with anti-SEMA3F alongside NRP2 staining to evaluate receptor-ligand distribution .

For tumor samples:

• Comparison with normal adjacent tissue is recommended as SEMA3F expression correlates with tumor stage in lung cancer .

• In breast cancer specimens, co-staining for NRP1/NRP2 alongside SEMA3F provides valuable information about potential signaling activity.

For all tissues, appropriate negative controls (isotype control antibodies) are essential for result interpretation, as demonstrated in lung section analysis from COPD patients .

How can I optimize Western blot protocols for detecting SEMA3F protein?

Optimizing Western blot protocols for SEMA3F detection requires attention to several key factors:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • For secreted SEMA3F, concentrate cell culture supernatants using TCA precipitation or centrifugal filters

• Gel selection and transfer:

  • Use 8-10% SDS-PAGE gels to properly resolve the 88.4 kDa SEMA3F protein

  • Transfer to PVDF membranes at lower amperage (250 mA) for longer duration (2 hours) to ensure complete transfer of larger proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Dilute primary anti-SEMA3F antibody according to manufacturer recommendations (typically 1:500-1:2000)

  • Extend primary antibody incubation to overnight at 4°C for improved signal

  • Use gentle agitation during all incubation steps

• Detection optimization:

  • For low abundance samples, consider enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Exposure times may need extension (1-5 minutes) for optimal band visualization

• Controls:

  • Include positive controls (e.g., recombinant SEMA3F protein)

  • For specificity verification, include samples from tissues known to express SEMA3F abundantly

Many commercially available anti-SEMA3F antibodies have been validated specifically for Western blot applications, making this technique particularly reliable for SEMA3F detection .

What methods are effective for studying SEMA3F-mediated cell migration and repulsion?

Several specialized methods have proven effective for investigating SEMA3F's effects on cell migration and repulsion:

• Three-dimensional co-culture system:

  • Create aggregates of cells expressing SEMA3F and control cells

  • Culture these with target cells (e.g., cancer cell lines) in a three-dimensional matrix

  • Monitor directional migration over 3-day periods

  • This approach has successfully demonstrated that C100 breast cancer cells do not migrate toward SEMA3F-expressing cell aggregates

• Stripe assay adaptation:

  • Immobilize SEMA3F on poly-l-lysine-coated glass coverslips in alternating stripes

  • Overlay with target cells and observe their distribution after 24 hours

  • Time-lapse microscopy can reveal the dynamic process of cells initially attaching equally but subsequently migrating away from SEMA3F-containing stripes

• Antibody blocking experiments:

  • Include anti-NRP1 or anti-NRP2 antibodies in migration assays to determine which receptor mediates observed effects

  • In C100 cells, anti-NRP2 antibodies specifically blocked SEMA3F's repulsive effect

• In vivo neutrophil tracking:

  • In zebrafish and murine models, overexpression of SEMA3F affects neutrophil migration speeds

  • For neutrophil retention studies in inflamed tissues, combining SEMA3F treatment with appropriate timing for neutrophil counting in bronchoalveolar lavage fluid provides quantitative data on SEMA3F's effects

These methodologies can be applied to different cell types to assess SEMA3F's cell-specific effects on migration, adhesion, and morphology.

How can anti-SEMA3F antibodies be used to investigate the role of SEMA3F in neutrophilic inflammation?

Anti-SEMA3F antibodies have been instrumental in elucidating SEMA3F's role in neutrophilic inflammation through several advanced approaches:

• Temporal expression analysis:

  • Use anti-SEMA3F antibodies to track expression changes in neutrophils before and after exposure to proinflammatory mediators

  • This reveals how SEMA3F upregulation correlates with inflammatory progression

• Compartmental localization studies:

  • In lung injury models, anti-SEMA3F antibodies help quantify SEMA3F distribution across vascular, interstitial, and alveolar compartments

  • This defines where SEMA3F exerts its effects on neutrophil retention

• Mechanistic intervention studies:

  • After establishing baseline SEMA3F expression, use neutralizing anti-SEMA3F antibodies to block endogenous SEMA3F function

  • This approach helps determine if inhibiting SEMA3F accelerates inflammation resolution

• Receptor co-localization analysis:

  • Dual staining with anti-SEMA3F and anti-NRP2 antibodies in inflamed tissues reveals receptor-ligand interactions

  • In COPD patient samples, this approach has helped establish the pathophysiological relevance of SEMA3F signaling

• Neutrophil retention quantification:

  • Combine anti-SEMA3F staining with neutrophil markers and migration tracking to correlate SEMA3F expression with neutrophil migratory behavior

  • This methodology has demonstrated that exogenous SEMA3F administration increases neutrophil counts in bronchoalveolar lavage samples 48 hours after introduction

These techniques collectively demonstrate how SEMA3F actively participates in neutrophil retention at inflammatory sites, potentially offering new therapeutic targets for conditions like COPD.

What approaches can be used to study the competition between SEMA3F and VEGF for neuropilin binding?

The competitive binding between SEMA3F and VEGF for neuropilin receptors represents an important regulatory mechanism that can be investigated through several sophisticated approaches:

• Competitive binding assays:

  • Use purified recombinant SEMA3F, VEGF, and soluble neuropilin domains

  • Pre-incubate labeled VEGF with neuropilins, then add increasing concentrations of SEMA3F

  • Measure displacement using techniques like surface plasmon resonance (SPR)

• Cell-based competition studies:

  • Expose cells expressing NRP1/NRP2 to both SEMA3F and VEGF at varying ratios

  • Use anti-SEMA3F and anti-VEGF antibodies to immunoprecipitate receptor complexes

  • Analyze the composition of precipitated complexes to determine preferential binding

• Functional antagonism assessment:

  • Since SEMA3F inhibits cell spreading while VEGF promotes it, quantitative cell spreading assays can reveal the functional balance between these factors

  • Pre-treat cells with anti-SEMA3F antibodies to block endogenous SEMA3F, then observe how VEGF responses are affected

• Receptor domain mapping:

  • Using domain-specific antibodies against different regions of neuropilins

  • Determine which epitopes are critical for SEMA3F versus VEGF binding

  • This helps identify the structural basis for competition

• Live-cell imaging with fluorescently-tagged proteins:

  • Create fluorescent fusion proteins for SEMA3F, VEGF, and neuropilins

  • Visualize binding dynamics in real-time using techniques like FRET (Förster Resonance Energy Transfer)

Research has shown that VEGF can oppose SEMA3F's inhibitory effects on cell spreading, suggesting these factors maintain a delicate balance in regulating cellular behaviors .

How can researchers investigate SEMA3F's potential tumor suppressor activity using antibodies?

Investigating SEMA3F's tumor suppressor activity requires multifaceted approaches involving anti-SEMA3F antibodies:

• Expression correlation studies:

  • Use anti-SEMA3F antibodies for immunohistochemical analysis of tumor tissue microarrays

  • Correlate SEMA3F expression levels with tumor stage, grade, and patient outcomes

  • This approach has revealed that loss of SEMA3F is associated with higher stages in lung cancer

• Functional restoration experiments:

  • In tumor cell lines with low SEMA3F expression, reintroduce SEMA3F and assess:

    • Changes in proliferation rates

    • Alterations in cell-cell contacts

    • Modifications to adhesion molecule distribution (E-cadherin, β-catenin)

  • Use anti-SEMA3F antibodies to confirm successful expression

• Mechanistic pathway analysis:

  • After SEMA3F treatment, use antibodies against signaling intermediates to track pathway activation

  • For example, in MCF7 cells, SEMA3F causes delocalization of membrane-associated E-cadherin and β-catenin, disrupting cell contacts

• In vivo tumor model assessment:

  • Generate xenograft models using SEMA3F-expressing and control tumor cells

  • Use anti-SEMA3F antibodies for immunohistochemical analysis of tumor sections

  • Correlate SEMA3F expression with tumor growth, invasion, and metastasis

• Receptor-dependency studies:

  • Combine anti-SEMA3F treatment with anti-NRP1 or anti-NRP2 blocking antibodies

  • Determine which receptor mediates the tumor suppressive effects

  • Studies show NRP2 mediates SEMA3F's repulsive effect on C100 breast cancer cells

These approaches collectively demonstrate how SEMA3F functions in preventing tumor cell spreading and attachment to stroma, suggesting it acts as a barrier to tumor progression during early tumorigenesis .

What are common challenges in detecting SEMA3F and how can they be addressed?

Researchers frequently encounter several challenges when detecting SEMA3F that can be systematically addressed:

Challenge 1: Low signal intensity

• Causes: Low endogenous expression levels, antibody sensitivity issues

• Solutions:

  • Concentrate samples through immunoprecipitation before Western blot

  • Use signal amplification systems (TSA for IHC, enhanced ECL for Western blot)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Consider using more sensitive polyclonal antibodies that recognize multiple epitopes

Challenge 2: Multiple bands in Western blot

• Causes: Isoform detection, proteolytic processing, glycosylation variants

• Solutions:

  • Verify band specificity using recombinant SEMA3F as positive control

  • Use domain-specific antibodies to distinguish isoforms

  • Include protein deglycosylation treatment to eliminate glycosylation-based heterogeneity

  • Remember SEMA3F has up to two reported isoforms and runs at approximately 88.4 kDa

Challenge 3: Background staining in IHC/ICC

• Causes: Cross-reactivity, non-specific binding, endogenous peroxidase activity

• Solutions:

  • Extend blocking time (5% normal serum, 2 hours)

  • Titrate antibody concentration to optimize signal-to-noise ratio

  • Include appropriate isotype control antibodies as demonstrated in lung sections from COPD patients

  • Use fluorescent secondary antibodies to reduce tissue autofluorescence issues

Challenge 4: Inconsistent results across different antibodies

• Causes: Epitope accessibility differences, varying affinities

• Solutions:

  • Validate findings using multiple independent antibodies targeting different SEMA3F epitopes

  • Consider antibody combinations for comprehensive detection

  • Document specific clone/catalog information in publications for reproducibility

How should researchers interpret changes in SEMA3F expression levels in different experimental contexts?

Interpreting changes in SEMA3F expression requires contextual analysis across different experimental systems:

• In inflammatory conditions:

  • Increased SEMA3F expression by neutrophils in response to proinflammatory mediators suggests an active role in inflammation persistence

  • Neutrophil upregulation of SEMA3F following recruitment to inflamed lung indicates a potential feedback mechanism

  • Interpretation should consider both the source of SEMA3F and its target cells

• In cancer models:

  • Decreased SEMA3F expression correlates with advanced tumor stages in lung cancer, suggesting loss contributes to disease progression

  • Expression changes should be interpreted relative to normal adjacent tissue

  • Consider receptor (NRP1/NRP2) expression changes alongside SEMA3F alterations for comprehensive pathway analysis

• In developmental systems:

  • Temporal and spatial expression patterns may indicate roles in tissue organization

  • Interpret in context of known axon guidance functions of semaphorins

• Quantitative considerations:

  • Western blot densitometry should be normalized to appropriate housekeeping proteins

  • For secreted SEMA3F in culture media, normalize to total cellular protein or cell number

  • For tissue sections, consider using digital pathology quantification with appropriate controls

• Experimental manipulations:

  • Overexpression studies should confirm protein levels by Western blot to complement mRNA analysis

  • Knockout/knockdown studies should verify the extent of SEMA3F reduction

  • Exogenous SEMA3F administration, as demonstrated in murine models, allows assessment of dose-dependent effects

What controls should be included when using anti-SEMA3F antibodies in complex experimental systems?

Robust experimental design with appropriate controls is essential when working with anti-SEMA3F antibodies:

For Western blot experiments:

• Positive control: Recombinant SEMA3F protein or lysate from cells with confirmed high SEMA3F expression

• Negative control: Lysate from SEMA3F knockout cells or tissues

• Loading control: Probing for housekeeping proteins (β-actin, GAPDH) on the same membrane

• Antibody specificity control: Pre-absorption of antibody with recombinant SEMA3F

For immunohistochemistry/immunofluorescence:

• Isotype control: Primary antibody replaced with matched isotype from same species at equivalent concentration

• No primary antibody control: Omission of primary antibody while maintaining all other steps

• Positive tissue control: Known SEMA3F-expressing tissue processed identically

• Knockout/knockdown control: When available, tissue from SEMA3F-deficient organisms

For functional studies:

• Receptor blocking controls: Include anti-NRP1 and anti-NRP2 antibodies to verify receptor specificity, as demonstrated in studies showing NRP2-dependence of SEMA3F's repulsive effect on C100 cells

• Specificity controls: Include related semaphorins (e.g., Sema3A, Sema3C) to confirm SEMA3F-specific effects

• Dose-response controls: Use multiple concentrations of SEMA3F to establish relationship between concentration and biological effect

• Timing controls: Analyze effects at multiple timepoints, as demonstrated in the 48-hour and 72-hour analyses in acute lung injury models

These controls ensure that observed effects are specifically attributable to SEMA3F and its signaling pathways.

How might anti-SEMA3F antibodies be used to develop therapeutic strategies for inflammatory diseases?

The emerging understanding of SEMA3F's role in neutrophil retention at inflammatory sites opens several therapeutic avenues:

• Targeted neutralization approach:

  • Develop neutralizing anti-SEMA3F antibodies to promote neutrophil clearance from inflamed tissues

  • This strategy could benefit chronic inflammatory conditions like COPD where neutrophil persistence contributes to pathology

  • Testing would involve confirming antibody specificity with Western blot, then validating functional neutralization in cell-based assays

• Compartment-specific targeting:

  • Design antibody-based therapies that specifically target SEMA3F in alveolar spaces for lung diseases

  • Research has shown that exogenous SEMA3F administered to the alveolar compartment increases neutrophil retention, suggesting blockade could reverse this effect

• Receptor-targeted approaches:

  • Develop antibodies targeting the SEMA3F-binding domain of NRP2

  • Research demonstrating that anti-NRP2 antibodies block SEMA3F's effects on neutrophil migration provides proof-of-concept

• Combination therapies:

  • Pair anti-SEMA3F approaches with existing anti-inflammatory therapies

  • Design studies to determine if SEMA3F neutralization enhances the efficacy of current treatments

• Biomarker development:

  • Use anti-SEMA3F antibodies to develop assays measuring SEMA3F levels in patient samples

  • Correlate levels with disease severity and treatment response

Developing these therapeutic strategies requires careful consideration of timing, as neutrophil recruitment is initially beneficial for host defense before becoming pathological in chronic inflammation.

What novel approaches are being developed to study SEMA3F's interactions with its co-receptors and signaling partners?

Cutting-edge techniques are expanding our understanding of SEMA3F's complex interaction network:

• Proximity labeling approaches:

  • BioID or APEX2 fusion proteins with SEMA3F to identify proteins in close proximity

  • This reveals novel interaction partners beyond the known neuropilin receptors

  • Verification of interactions requires co-immunoprecipitation with anti-SEMA3F antibodies

• Advanced imaging techniques:

  • Super-resolution microscopy combined with antibody staining to visualize SEMA3F-receptor clusters at nanoscale resolution

  • Live-cell FRET imaging to monitor real-time interactions between SEMA3F and its receptors

  • Correlative light and electron microscopy (CLEM) to connect SEMA3F localization with cellular ultrastructure

• Receptor complex isolation:

  • Blue-native PAGE combined with anti-SEMA3F and anti-neuropilin antibodies to isolate intact signaling complexes

  • Mass spectrometry analysis of these complexes to identify additional components

  • Crosslinking mass spectrometry to map precise interaction interfaces

• Structural biology approaches:

  • Cryo-EM analysis of SEMA3F-receptor complexes, using antibody fragments to stabilize interactions

  • Hydrogen-deuterium exchange mass spectrometry to map dynamic binding interfaces

• Receptor competition studies:

  • Quantitative binding assays using surface plasmon resonance to determine binding kinetics between SEMA3F and its receptors

  • Competition assays with VEGF to better understand the molecular basis for their antagonistic relationship

These approaches collectively provide a systems-level understanding of how SEMA3F integrates into broader signaling networks controlling cell motility, adhesion, and inflammatory responses.

How can researchers best integrate SEMA3F studies with broader investigations of the semaphorin family?

Integrating SEMA3F research within the broader semaphorin family context requires strategic approaches:

• Comparative expression analysis:

  • Use antibody panels against multiple semaphorins (SEMA3A, SEMA3B, SEMA3C, SEMA3F) to create expression profiles across tissues

  • This identifies unique versus overlapping expression domains

  • Studies have shown distinct effects between SEMA3F and other semaphorins (SEMA3A, SEMA3C) on C100 cell migration

• Receptor selectivity mapping:

  • Determine binding preferences of different semaphorins for shared receptors

  • Quantify competitive or cooperative binding between semaphorins for neuropilins

  • Use blocking antibodies against specific neuropilin domains to map binding sites

• Combinatorial functional assessment:

  • Systematically test effects of semaphorin combinations on cellular behaviors

  • This addresses physiological scenarios where multiple semaphorins are present

  • Use the stripe assay methodology adapted for tumor cell migration to compare responses to different semaphorins

• Evolutionary analysis:

  • Compare functions of orthologous semaphorins across species

  • SEMA3F orthologs have been identified in mouse, rat, bovine, frog, and chimpanzee

  • Use antibodies specifically validated for cross-species reactivity

• Pathway integration studies:

  • Map downstream signaling pathways activated by different semaphorins

  • Identify convergent and divergent signaling nodes

  • Use phospho-specific antibodies to track pathway activation after SEMA3F treatment

This integrated approach provides a comprehensive understanding of how SEMA3F functions within the broader context of semaphorin biology, revealing both unique and shared mechanisms across this important protein family.

SEMA3F Receptor Binding Properties and Functions

SEMA3F Expression Across Tissue Types

SEMA3F Antibody Applications and Optimization Parameters